Fujifilm Holdings Corp said on Thursday that it had signed a manufacturing contract agreement with U.S.-based firm VLP Therapeutics for a COVID-19 vaccine formulation.
FILE PHOTO: Fujifilm's company logo is seen at its exhibition hall nearby the headquarters of Fujifilm Holdings Corp in Tokyo, Japan June 12, 2017. REUTERS/Kim Kyung-Hoon/File Photosaid on Thursday that it had signed a manufacturing contract agreement with U.S.-based firm VLP Therapeutics for a COVID-19 vaccine formulation.
VLP’s RNA-based vaccine candidate was selected for funding by the Japan Agency for Medical Research and Development.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Moderna COVID-19 vaccine appears safe, shows signs of working in older adults - studyResults from an early safety study of Moderna Inc's coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots,...
Weiterlesen »
Moderna COVID-19 vaccine appears safe, shows signs of working in older adults - studyResults from an early safety study of Moderna Inc's coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots, researchers...
Weiterlesen »
Moderna says COVID-19 vaccine unlikely to be ready before U.S. election - FTModerna Inc will not be ready to apply for emergency authorization for its potential COVID-19 vaccine before the U.S. presidential election in November, the Financial Times reported on Wednesday, citing the company's chief executive officer.
Weiterlesen »
GlaxoSmithKline CEO optimistic COVID-19 vaccine widely available in 2021The chief executive of GlaxoSmithKline, the world's largest maker of vaccines, said she was optimistic the industry will be able to make an immunisation against COVID-19 widely available next year.
Weiterlesen »
CureVac plans global late-stage COVID-19 vaccine trial in fourth quarterGermany's CureVac NV said on Tuesday it has started a mid-stage study testing its experimental coronavirus vaccine and plans to begin a decisive global trial with about 30,000 volunteers in the fourth quarter.
Weiterlesen »
Russian scientist behind COVID-19 vaccine defends 'wartime' roll-outRussia plans to share preliminary results of its COVID-19 vaccine trial based on the first six weeks of monitoring participants, raising the tempo in an already frenzied global race to end the pandemic.
Weiterlesen »